Martin Bellgardt

The international, prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: results from the first 300 patients

Ricard Ferrer, Matthias Thielmann, Moritz Unglaube, Thomas Kirschning et autres

Abstract Introduction Blood purification techniques are being investigated as adjunctive options in critically ill patients not only to treat severe inflammation but also to remove harmful substances such as myoglobin in rhabdomyolysis. Yet, the available evidence is limited, and further research is …

es, de, pt, it, at, bz, fr, ro, us, be (code pays fourni par la source)

The International, Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: Interim Results in Patients with Septic Shock

Ricard Ferrer, Thomas Kirschning, Moritz Unglaube, Ulf Guenther et autres

Background: The international prospective COSMOS Registry (NCT05146336) collects real-world data on CytoSorb® (CS) hemoadsorption utilization patterns and outcomes in critically ill patients. This analysis focuses on patients with septic shock. Methods: Following informed consent, data was systematically collected before, during, and after …

es, de, pt, it, bz, fr, ro, us, be (code pays fourni par la source)

Hemoadsorption therapy in severe rhabdomyolysis: a report from the international, prospective COSMOS (CytOSorb ® TreatMent of Critically ill PatientS) registry

Ricard Ferrer, Bartosz Tyczynski, Julian Kreutz, Christina Scharf et autres

Severe rhabdomyolysis is associated with an increased risk of acute kidney injury (AKI) and mortality. Hemoadsorption may reduce myoglobin levels and mitigate AKI. The COSMOS registry is a prospective, multicenter, observational study evaluating hemoadsorption with CytoSorb® (CS) in critically ill patients. Consecutive …

es, de, pt, us, be (code pays fourni par la source)

The International, Prospective COSMOS (CytOSorb ® TreatMent Of Critically Ill PatientS) Registry: Results from the first 300 patients

Ricard Ferrer, Matthias Thielmann, Moritz Unglaube, Thomas Kirschning et autres

de, at, us, es, it, bz, fr, ro, be (code pays fourni par la source)

The international, prospective CytOSorbⓇ treatMent Of critically ill patientS (COSMOS) registry: Interim results from the first 150 patients

Ricard Ferrer, Matthias Thielmann, Andreas Kribben, Moritz Unglaube et autres

Background The CytOSorb Ⓡ treatMent Of critically ill patientS (COSMOS) registry is an observational, prospective, multicenter, international real-world data collection platform executed in countries where the CytoSorb Ⓡ (CS) 300 mL device is approved and routinely used in everyday clinical practice. This …

es, de, it, bz, fr, ro, us, be (code pays fourni par la source)

Volatile Anesthetic Sedation for Critically Ill Patients

Brian O’Gara, Christina Boncyk, Andreas Meiser, Angela Jerath et autres

Volatile anesthetics have multiple properties that make them useful for sedation in the intensive care unit. The team-based approach to volatile anesthetic sedation leverages these properties to provide a safe and effective alternative to intravenous sedatives.

us, nl, ar, de, ca, fr (code pays fourni par la source)

The International, Prospective Cosmos (Cytosorb® Treatment of Critically Ill Patients) Registry: Interim Results from the First 150 Patients

Ricard Ferrer, Matthias Thielmann, Andreas Kribben, Moritz Unglaube et autres

es, de, it, be (code pays fourni par la source)

Authors response: “ICU- and ventilator-free days with isoflurane or propofol as a primary sedative – A post-hoc analysis of a randomized controlled trial”

Martin Bellgardt, Fabian Onyeche, Peter Sackey, Hendrik Bracht

de, se (code pays fourni par la source)

ICU- and ventilator-free days with isoflurane or propofol as a primary sedative – A post- hoc analysis of a randomized controlled trial

Hendrik Bracht, Andreas Meiser, Jan Wallenborn, Ulf Guenther et autres

PURPOSE: To compare ICU-free (ICU-FD) and ventilator-free days (VFD) in the 30 days after randomization in patients that received isoflurane or propofol without receiving the other sedative. MATERIALS AND METHODS: A recent randomized controlled trial (RCT) compared inhaled isoflurane via the Sedaconda® …

de, us, at, si, se (code pays fourni par la source)

Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus

Shuyuan Liu, Shengyong Xu, Lu Yin, Ting Yang et autres

Continuous renal replacement therapy (CRRT) is widely used for treating critically-ill patients in the emergency department in China. Anticoagulant therapy is needed to prevent clotting in the extracorporeal circulation during CRRT. Regional citrate anticoagulation (RCA) has been shown to potentially be safer …

cn, us, gb, de (code pays fourni par la source)

Ventilatory Effects of Isoflurane Sedation via the Sedaconda ACD-S versus ACD-L: A Substudy of a Randomized Trial

Lukas M. Müller‐Wirtz, Tobias Becher, Ulf Günther, Martin Bellgardt et autres

Devices used to deliver inhaled sedation increase dead space ventilation. We therefore compared ventilatory effects among isoflurane sedation via the Sedaconda ACD-S (internal volume: 50 mL), isoflurane sedation via the Sedaconda ACD-L (100 mL), and propofol sedation with standard mechanical ventilation with …

us, de, se (code pays fourni par la source)

ICU- and Ventilator-Free Days with Isoflurane or Propofol as a Primary Sedative – A Post- Hoc Analysis of a Randomized Controlled Trial

Hendrik Bracht, Andreas Meiser, Jan Wallenborn, Ulf Guenther et autres

de, at, si, se (code pays fourni par la source)